株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性冠症候群 (ACS) の世界市場:2015-2019年

Global Acute Coronary Syndrome (ACS) Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 326301
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
急性冠症候群 (ACS) の世界市場:2015-2019年 Global Acute Coronary Syndrome (ACS) Market 2015-2019
出版日: 2015年03月18日 ページ情報: 英文 97 Pages
概要

世界の急性冠症候群 (ACS) の市場は2014年から2019年にかけて13.24%のCAGRで成長すると予測されています。

当レポートでは、世界の急性冠症候群 (ACS) の市場について調査し、急性冠症候群 (ACS) の概要、分類、診断法、管理法、主な薬剤とパイプラインの状況、市場規模の推移と予測、地域別の動向、市場成長への各種影響因子の分析、競合環境と主要企業の市場シェア、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾患概要

  • 疾患について
  • 疾患の負担
  • 病因
  • 病理生理
    • 心筋機能不全
    • 心筋梗塞
    • 電気的機能不全
  • 予後
  • 疫学
    • 冠動脈疾患の有病率
  • 診断
    • 心電図 (ECG)
    • 血液検査
    • 核医学診断
    • CT
  • 管理

第7章 ACSパイプライン環境

  • 主なパイプライン分子

第8章 市場環境

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 ECGアウトプット別市場

第10章 地域別市場

第11章 購入基準

第12章 市場成長促進要因

第13章 成長促進要因とその影響

第14章 市場の課題

第15章 成長促進要因と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly
    • GlaxoSmithKline
    • Sanofi
  • その他の有力ベンダー

第19章 主要ベンダーの分析

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
    • 主要データ
    • 事業概要
    • 事業区分
    • 事業区分別収益
    • 地域別収益
    • 事業戦略
    • 主な発展動向
    • SWOT分析、など

第20章 関連レポート

図表

目次
Product Code: IRTNTR5471

About ACS

ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.

TechNavio's analysts forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.

Covered in this Report

The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.

TechNavio's report, the Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Astra Zeneca
  • BMS
  • Eli Lilly
  • GSK
  • Sanofi

Other Prominent Vendors

  • AbbVie
  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Portola Pharmaceuticals
  • Teva Pharmaceutical

Market Driver

  • Increase in Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Multiple Patent Expirations
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Burden of Disease
  • 06.3. Etiology
  • 06.4. Pathophysiology
    • 06.4.1. Myocardial Dysfunction
    • 06.4.2. MI
    • 06.4.3. Electrical Dysfunction
  • 06.5. Prognosis
  • 06.6. Epidemiology
    • 06.6.1. Prevalence of Coronary Artery Disease
  • 06.7. Diagnosis
    • 06.7.1. ECG
    • 06.7.2. Blood Tests
    • 06.7.3. Nuclear Scan
    • 06.7.4. CT
  • 06.8. Management

07. ACS Pipeline Landscape

  • 07.1. Key Pipeline Molecules

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by ECG Output

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. AstraZeneca
    • 18.2.2. Bristol-Myers Squibb
    • 18.2.3. Eli Lilly
    • 18.2.4. GlaxoSmithKline
    • 18.2.5. Sanofi
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. AstraZeneca
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Business Segmentation by Revenue 2011-2013
    • 19.1.5. Revenue by Geography
    • 19.1.6. Business Strategy
    • 19.1.7. Key Developments
    • 19.1.8. SWOT Analysis
  • 19.2. Bristol-Myers Squibb
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Key Product Offerings
    • 19.2.4. Revenue by Geography
    • 19.2.5. Business Strategy
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
  • 19.3. Eli Lilly
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue
    • 19.3.4. Revenue by Geography
    • 19.3.5. Business Strategy
    • 19.3.6. Key Information
    • 19.3.7. SWOT Analysis
  • 19.4. GlaxoSmithKline
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Revenue by Geography
    • 19.4.6. Pipeline Products
    • 19.4.7. Business Strategy
    • 19.4.8. Key Information
    • 19.4.9. SWOT Analysis
  • 19.5. Sanofi
    • 19.5.1. Key Facts
    • 19.5.2. Business Description
    • 19.5.3. Business Segmentation
    • 19.5.4. Revenue by Business Segmentation
    • 19.5.5. Revenue Comparison 2012 and 2013
    • 19.5.6. Revenue by Geography
    • 19.5.7. Business Strategy
    • 19.5.8. Key Developments
    • 19.5.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Spectrum of ACS
  • Exhibit 3: Overview of ACS
  • Exhibit 4: Pathogenesis of ACS
  • Exhibit 5: Hospitalized Incident Cases of ACS 2014-2019 (millions)
  • Exhibit 6: Epidemiologic Transition of CV Diseases
  • Exhibit 7: Initial Drug Therapy for ACS
  • Exhibit 8: Adjunctive Drug Therapy for ACS
  • Exhibit 9: Surgery and Other Procedures
  • Exhibit 10: Snapshot of Global ACS Market 2014
  • Exhibit 11: Global ACS Market 2014-2019 (US$ billion)
  • Exhibit 12: Global ACS Market Share of Branded and Generic Drugs 2014 and 2019 (in Percent)
  • Exhibit 13: Segmentation of Global ACS Market by ECG Output
  • Exhibit 14: Diagrammatic Representation of STEMI, NSTEMI, and UA
  • Exhibit 15: Segmentation of Global ACS Market by ECG Output 2014
  • Exhibit 16: Global ACS Market by Geography 2014
  • Exhibit 17: Drivers of Global ACS Market
  • Exhibit 18: Comparison of Elderly Population 2012 and 2050 (Aged 65 and Older)
  • Exhibit 19: Challenges in Global ACS Market
  • Exhibit 20: Trends in Global ACS Market
  • Exhibit 21: Global Revenue of AstraZeneca for CV and Metabolic Diseases 2011-2013 (US$ million)
  • Exhibit 22: Estimated Filings of Brilinta/Brilique
  • Exhibit 23: Line Extensions for Brilinta/Brilique
  • Exhibit 24: Global Revenue of Brilinta/Brilique by AstraZeneca 2011-2013 (US$ million)
  • Exhibit 25: Global Revenue of Plavix by Bristol-Myers Squibb 2010-2012 (US$ million)
  • Exhibit 26: Revenue of Eli Lilly by Therapeutic Area 2013
  • Exhibit 27: Global Revenue of Effient by Eli Lilly 2010-2013 (US$ million)
  • Exhibit 28: Global Revenue of Arixtra by GlaxoSmithKline 2011-2013 (US$ million)
  • Exhibit 29: Global Revenue of Plavix by Sanofi 2011-2013 (US$ million)
  • Exhibit 30: Global Revenue of Lovenox by Sanofi 2011-2013 (US$ million)
  • Exhibit 31: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 32: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 33: AstraZeneca: Revenue by Geography 2013
  • Exhibit 34: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 35: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 36: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 37: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 38: Eli Lilly: Revenue by Geography 2013
  • Exhibit 39: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 40: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 41: GlaxoSmithKline: Revenue by Geography 2013
  • Exhibit 42: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 43: Sanofi: Business Segmentation
  • Exhibit 44: Sanofi: Revenue by Business Segmentation 2013
  • Exhibit 45: Sanofi: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 46: Sanofi: Revenue by Geographical Segmentation 2013
Back to Top